DLX 1
Alternative Names: AAZ; DLX-001; DLX-1Latest Information Update: 11 Dec 2023
At a glance
- Originator Delix Therapeutics
- Class Antidepressants; Neuropsychotherapeutics; Small molecules
- Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants; Serotonin 5-HT2A receptor agonists; Serotonin receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I CNS disorders; Major depressive disorder
Most Recent Events
- 06 Dec 2023 Interim pharmacokinetics and adverse events data from a phase I trial in healthy volunteers presented at the American College of Neuropsychopharmacology Annual Meeting (ACNP-2023)
- 06 Dec 2023 Pharmacodynamics and pharmacokinetics data from a preclinical study presented at the American College of Neuropsychopharmacology Annual Meeting (ACNP-2023)
- 20 Jun 2023 Delix Therapeutics announces intention to submit an Investigational New Drug (IND) application to the US FDA for DLX 1